{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:09:03Z","timestamp":1792595343221,"version":"4.5.0"},"reference-count":72,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T00:00:00Z","timestamp":1501718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["U01 AG024904"],"award-info":[{"award-number":["U01 AG024904"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-12-2-0012"],"award-info":[{"award-number":["W81XWH-12-2-0012"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0182098","type":"journal-article","created":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T14:05:46Z","timestamp":1501769146000},"page":"e0182098","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":52,"title":["A multivariate predictive modeling approach reveals a novel CSF peptide signature for both Alzheimer's Disease state classification and for predicting future disease progression"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0933-1837","authenticated-orcid":true,"given":"Daniel A.","family":"Llano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Bundela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raksha A.","family":"Mudar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viswanath","family":"Devanarayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,8,3]]},"reference":[{"key":"ref1","author":"C Ritchie","year":"2014"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","article-title":"Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS\u2013ADRDA criteria","volume":"6","author":"B Dubois","year":"2007","journal-title":"The Lancet Neurology"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3389\/fnagi.2014.00287","article-title":"Improving CSF biomarkers\u2019 performance for predicting progression from mild cognitive impairment to Alzheimer\u2019s disease by considering different confounding factors: a meta-analysis","volume":"6","author":"D Ferreira","year":"2014","journal-title":"Frontiers in Aging Neuroscience"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1001\/jama.289.16.2094","article-title":"Decreased \u03b2-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease","volume":"289","author":"T Sunderland","year":"2003","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/00002093-200207000-00003","article-title":"Relationships among cerebrospinal fluid biomarkers in dementia of the Alzheimer type","volume":"16","author":"JG Csernansky","year":"2002","journal-title":"Alzheimer Disease & Associated Disorders"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000008156","article-title":"Age-Dependent Change in the Levels of A\u03b240 and A\u03b242 in Cerebrospinal Fluid from Control Subjects, and a Decrease in the Ratio of A\u03b242 to A\u03b240 Level in Cerebrospinal Fluid from Alzheimer\u2019s Disease Patients","volume":"43","author":"R Fukuyama","year":"2000","journal-title":"European Neurology"},{"key":"ref7","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2014.00287","article-title":"Improving CSF biomarkers\u2019 performance for predicting progression from Mild Cognitive Impairment to Alzheimer\u2019s disease by considering different confounding factors: a meta-analysis","volume":"6","author":"D Ferreira","year":"2014","journal-title":"Frontiers in aging neuroscience"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.mad.2005.09.022","article-title":"Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers","volume":"127","author":"L Parnetti","year":"2006","journal-title":"Mechanisms of ageing and development"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3233\/JAD-2007-12307","article-title":"Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years","volume":"12","author":"H Zetterberg","year":"2007","journal-title":"Journal of Alzheimer's Disease"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/YCO.0b013e32835f6747","article-title":"Cerebrospinal fluid biomarkers for pathological processes in Alzheimer's disease","volume":"26","author":"C Ros\u00e9n","year":"2013","journal-title":"Current opinion in psychiatry"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1016\/j.jprot.2010.07.001","article-title":"Secretome proteomics for discovery of cancer biomarkers","volume":"73","author":"M Makridakis","year":"2010","journal-title":"Journal of proteomics"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"e15573","DOI":"10.1371\/journal.pone.0015573","article-title":"Discovery and preclinical validation of salivary transcriptomic and proteomic biomarkers for the non-invasive detection of breast cancer","volume":"5","author":"L Zhang","year":"2010","journal-title":"PloS one"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1074\/mcp.R900006-MCP200","article-title":"Plasma membrane proteomics and its application in clinical cancer biomarker discovery","volume":"9","author":"R Leth-Larsen","year":"2010","journal-title":"Molecular & Cellular Proteomics"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/WAD.0b013e31826d597a","article-title":"Evaluation of plasma proteomic data for Alzheimer disease state classification and for the prediction of progression from mild cognitive impairment to Alzheimer disease","volume":"27","author":"DA Llano","year":"2013","journal-title":"Alzheimer Disease & Associated Disorders"},{"key":"ref15","article-title":"Targeted proteomics identifies liquid-biopsy signatures for extracapsular prostate cancer","volume":"7","author":"Y Kim","year":"2016","journal-title":"Nature Communications"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0079-6123(06)58004-5","article-title":"Functional genomics and proteomics in the clinical neurosciences: data mining and bioinformatics","volume":"158","author":"JH Phan","year":"2006","journal-title":"Progress in brain research"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"46ps42","DOI":"10.1126\/scitranslmed.3001249","article-title":"Recommendations for biomarker identification and qualification in clinical proteomics","volume":"2","author":"H Mischak","year":"2010","journal-title":"Science Translational Medicine"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1186\/1471-2105-11-594","article-title":"Addressing the challenge of defining valid proteomic biomarkers and classifiers","volume":"11","author":"M Dakna","year":"2010","journal-title":"BMC bioinformatics"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1681\/ASN.2006090956","article-title":"Advances in urinary proteome analysis and biomarker discovery","volume":"18","author":"D Fliser","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"e104625","DOI":"10.1371\/journal.pone.0104625","article-title":"Identification of urinary peptide biomarkers associated with rheumatoid arthritis","volume":"9","author":"A Stalmach","year":"2014","journal-title":"PloS one"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-1-4939-0404-4_12","article-title":"Screening for novel serum biomarker for monitoring disease activity in rheumatoid arthritis using iTRAQ technology-based quantitative proteomic approach","author":"S Serada","year":"2014","journal-title":"Arthritis Research: Methods and Protocols"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"6983","DOI":"10.1021\/ac500986t","article-title":"Multiplexing determination of small cell lung cancer biomarkers and their isovariants in serum by immunocapture LC-MS\/MS","volume":"86","author":"SB Torsetnes","year":"2014","journal-title":"Analytical Chemistry"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/JAD-2006-9309","article-title":"Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders","volume":"9","author":"F Abdi","year":"2006","journal-title":"Journal of Alzheimer's Disease"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"e18850","DOI":"10.1371\/journal.pone.0018850","article-title":"Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis","volume":"6","author":"R Craig-Schapiro","year":"2011","journal-title":"PLoS One"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00401-010-0667-0","article-title":"Novel CSF biomarkers for Alzheimer\u2019s disease and mild cognitive impairment","volume":"119","author":"WT Hu","year":"2010","journal-title":"Acta neuropathologica"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1750-1326-9-22","article-title":"Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics","volume":"9","author":"KR Wildsmith","year":"2014","journal-title":"Molecular Neurodegeneration"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.biopsych.2013.11.032","article-title":"Phosphorylated Tau-A\u03b2 42 Ratio as a Continuous Trait for Biomarker Discovery for Early-Stage Alzheimer\u2019s Disease in Multiplex Immunoassay Panels of Cerebrospinal Fluid","volume":"75","author":"O Harari","year":"2014","journal-title":"Biological psychiatry"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000323417","article-title":"Screening for new biomarkers for subcortical vascular dementia and Alzheimer\u2019s disease","volume":"1","author":"A \u00d6hrfelt","year":"2011","journal-title":"Dementia and geriatric cognitive disorders extra"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.molbrainres.2003.08.005","article-title":"Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease","volume":"118","author":"M Puchades","year":"2003","journal-title":"Molecular brain research"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1001\/archneur.56.3.303","article-title":"Mild cognitive impairment: clinical characterization and outcome","volume":"56","author":"RC Petersen","year":"1999","journal-title":"Archives of neurology"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.21610","article-title":"Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects","volume":"65","author":"LM Shaw","year":"2009","journal-title":"Annals of neurology"},{"key":"ref32","article-title":"Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF","author":"DS Spellman","year":"2015","journal-title":"Proteomics-Clinical Applications"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nbt.1546","article-title":"Multi-site assessment of the precision and reproducibility of multiple reaction monitoring\u2013based measurements of proteins in plasma","volume":"27","author":"TA Addona","year":"2009","journal-title":"Nature biotechnology"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","author":"Y Benjamini","year":"1995","journal-title":"Journal of the Royal Statistical Society Series B (Methodological)"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v033.i01","article-title":"Regularization paths for generalized linear models via coordinate descent","volume":"33","author":"J Friedman","year":"2010","journal-title":"Journal of statistical software"},{"key":"ref36","author":"B Efron","year":"1994"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nbt.1665","article-title":"The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models","volume":"28","author":"L Shi","year":"2010","journal-title":"Nature biotechnology"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","article-title":"Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families","volume":"261","author":"E Corder","year":"1993","journal-title":"Science"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1074\/mcp.M112.018861","article-title":"Total ApoE and ApoE4 isoform assays in an Alzheimer's disease case-control study by targeted mass spectrometry (n = 669): a pilot assay for methionine-containing proteotypic peptides","volume":"11","author":"R Simon","year":"2012","journal-title":"Molecular & Cellular Proteomics"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cca.2015.12.020","article-title":"Development of new quantitative mass spectrometry and semi-automatic isofocusing methods for the determination of Apolipoprotein E typing","volume":"454","author":"C Hirtz","year":"2016","journal-title":"Clinica Chimica Acta"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jchromb.2013.05.003","article-title":"Targeted human cerebrospinal fluid proteomics for the validation of multiple Alzheimer's disease biomarker candidates","volume":"930","author":"YS Choi","year":"2013","journal-title":"Journal of Chromatography B"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3109\/13547500903108423","article-title":"Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease","volume":"14","author":"AE Roher","year":"2009","journal-title":"Biomarkers"},{"key":"ref43","article-title":"Proteomic Analysis of Cerebrospinal Fluid in Alzheimer's Disease: Wanted Dead or Alive","author":"Z Ol\u00e1h","year":"2014","journal-title":"Journal of Alzheimer's Disease"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2174\/156720509788929318","article-title":"Proteomic analysis of Alzheimer\u2019s disease cerebrospinal fluid from neuropathologically diagnosed subjects","volume":"6","author":"CL Maarouf","year":"2009","journal-title":"Current Alzheimer research"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1001\/archneurol.2011.642","article-title":"Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations","volume":"69","author":"JM Ringman","year":"2012","journal-title":"Archives of neurology"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3233\/JAD-121384","article-title":"Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in Alzheimer's disease and vascular dementia","volume":"34","author":"B Olsson","year":"2013","journal-title":"Journal of Alzheimer's Disease"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.3233\/JAD-2010-101293","article-title":"CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease","volume":"22","author":"D Chiasserini","year":"2010","journal-title":"Journal of Alzheimer's Disease"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00406-013-0405-4","article-title":"Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer\u2019s disease","volume":"263","author":"L-H Guo","year":"2013","journal-title":"European archives of psychiatry and clinical neuroscience"},{"key":"ref49","first-page":"1","article-title":"Combined Plasma and Cerebrospinal Fluid Signature for the Prediction of Midterm Progression From Mild Cognitive Impairment to Alzheimer Disease","author":"B Lehallier","year":"2015","journal-title":"JAMA neurology"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"e0134368","DOI":"10.1371\/journal.pone.0134368","article-title":"A subset of cerebrospinal fluid proteins from a multi-analyte panel associated with brain atrophy, disease classification and prediction in Alzheimer\u2019s disease","volume":"10","author":"W Khan","year":"2015","journal-title":"PLoS One"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0009-9120(91)90571-U","article-title":"Serum and urinary human heart fatty acid-binding protein in acute myocardial infarction","volume":"24","author":"T Tanaka","year":"1991","journal-title":"Clinical biochemistry"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1373\/clinchem.2003.030361","article-title":"Brain-and heart-type fatty acid-binding proteins in the brain: tissue distribution and clinical utility","volume":"50","author":"MM Pelsers","year":"2004","journal-title":"Clinical Chemistry"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/bja\/aet149","article-title":"Heart-fatty acid-binding and tau proteins relate to brain injury severity and long-term outcome in subarachnoid haemorrhage patients","volume":"111","author":"E Zanier","year":"2013","journal-title":"British journal of anaesthesia"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s10571-010-9529-5","article-title":"Development of an ultra-rapid diagnostic method based on heart-type fatty acid binding protein levels in the CSF of CJD patients","volume":"30","author":"Y Matsui","year":"2010","journal-title":"Cellular and molecular neurobiology"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1007\/s00415-005-0725-z","article-title":"Release of brain\u2013type and heart\u2013type fatty acid\u2013binding proteins in serum after acute ischaemic stroke","volume":"252","author":"MT Wunderlich","year":"2005","journal-title":"Journal of neurology"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1089\/neu.2012.2791","article-title":"The prognostic significance of the serum biomarker heart-fatty acidic binding protein in comparison with s100b in severe traumatic brain injury","volume":"30","author":"B Walder","year":"2013","journal-title":"Journal of neurotrauma"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"e0175572","DOI":"10.1371\/journal.pone.0175572","article-title":"H-FABP: A new biomarker to differentiate between CT-positive and CT-negative patients with mild traumatic brain injury","volume":"12","author":"L Lagerstedt","year":"2017","journal-title":"PloS one"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"18957","DOI":"10.1074\/jbc.M113.527341","article-title":"FABP3 Protein Promotes-Synuclein Oligomerization Associated with 1-Methyl-1, 2, 3, 6-tetrahydropiridine-induced Neurotoxicity","volume":"2014","author":"N Shioda","year":"2014","journal-title":"J Biol Chem"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1212\/01.wnl.0000171450.97464.49","article-title":"Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD","volume":"65","author":"B Dickerson","year":"2005","journal-title":"Neurology"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.brainres.2009.01.058","article-title":"Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases","volume":"1265","author":"GN Yin","year":"2009","journal-title":"Brain research"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1469-7580.2010.01309.x","article-title":"Distribution of VGF peptides in the human cortex and their selective changes in Parkinson\u2019s and Alzheimer\u2019s diseases","volume":"217","author":"C Cocco","year":"2010","journal-title":"Journal of anatomy"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1001\/archneur.64.3.366","article-title":"Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment","volume":"64","author":"AH Simonsen","year":"2007","journal-title":"Archives of neurology"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1021\/pr501076j","article-title":"An Integrated Workflow for Multiplex CSF Proteomics and Peptidomics Identification of Candidate Cerebrospinal Fluid Biomarkers of Alzheimer\u2019s Disease","volume":"14","author":"M H\u00f6ltt\u00e4","year":"2014","journal-title":"Journal of proteome research"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"e26540","DOI":"10.1371\/journal.pone.0026540","article-title":"Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers","volume":"6","author":"H Jahn","year":"2011","journal-title":"PloS one"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/pmic.200300470","article-title":"A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease","volume":"3","author":"O Carrette","year":"2003","journal-title":"Proteomics"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2174\/138620705774962391","article-title":"Identification of novel biomarker candidates by differential peptidomics analysis of cerebrospinal fluid in Alzheimer's disease","volume":"8","author":"H Selle","year":"2005","journal-title":"Combinatorial chemistry & high throughput screening"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1471-2377-11-101","article-title":"Identification of a novel biomarker candidate, a 4.8-kDa peptide fragment from a neurosecretory protein VGF precursor, by proteomic analysis of cerebrospinal fluid from children with acute encephalopathy using SELDI-TOF-MS","volume":"11","author":"T Asano","year":"2011","journal-title":"BMC neurology"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.expneurol.2005.08.002","article-title":"Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF","volume":"196","author":"U R\u00fcetschi","year":"2005","journal-title":"Experimental neurology"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"P555","DOI":"10.1016\/j.jalz.2013.05.1084","article-title":"Genetic interaction analysis of Alzheimer's disease progression using phospho-tau as a covariate","volume":"9","author":"Y Sun","year":"2013","journal-title":"Alzheimer's & Dementia: The Journal of the Alzheimer's Association"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"615","DOI":"10.4236\/jbise.2013.66078","article-title":"Systematic analysis of diabetes-and glucose metabolism-related proteins and its application to Alzheimer's disease","volume":"6","author":"J Yang","year":"2013","journal-title":"Journal of Biomedical Science and Engineering"},{"key":"ref71","first-page":"226","article-title":"The blood-brain barrier and cerebral microcirculation in Alzheimer disease","volume":"4","author":"R Kalaria","year":"1991","journal-title":"Cerebrovascular and brain metabolism reviews"},{"key":"ref72","first-page":"1","article-title":"Accurate Prediction of Conversion to Alzheimer\u2019s Disease using Imaging, Genetic, and Neuropsychological Biomarkers","author":"J Dukart","year":"2015","journal-title":"Journal of Alzheimer's Disease"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0182098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T20:38:57Z","timestamp":1569962337000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0182098"}},"subtitle":[],"editor":[{"given":"Kewei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,8,3]]},"references-count":72,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,8,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0182098","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,3]]}}}